CD44 and prostate carcinoma: CUR inhibited the proliferation, invasion, and tumorigenicity of prostate cancer stem cells HuPCaSCs (CD44+/CD133+ subpopulation isolated from prostate cancer cell lines Du145 and 22RV1) by increasing the expression of miR-145, which prevents cell proliferation by decreasing Oct4 expression [143].